Wang Shunying,Dong Kuiran.Recent advances of targeted therapy for pediatric solid tumors[J].Journal of Clinical Pediatric Surgery,2023,22(07):611-618.[doi:10.3760/cma.j.cn101785-202304074-003]
靶向治疗在儿童实体肿瘤中的应用进展
- Title:
- Recent advances of targeted therapy for pediatric solid tumors
- 关键词:
- 实体肿瘤疗效评价标准; 分子靶向治疗; 外科手术; 儿童
- Keywords:
- Response Evaluation Criteria in Solid Tumors; Molecular Targeted Therapy; Surgical Procedures; Operative; Child
- 摘要:
- 近年来，靶向治疗在儿童实体肿瘤领域的应用突飞猛进，且已在部分肿瘤的治疗中取得了关键进展，为改善复发、耐药、手术无法切除的难治性肿瘤患儿生存情况带来了希望。本文以靶向治疗的多种载体为线索，基于近5年来靶向治疗在儿童实体肿瘤中的临床试验成果，对靶向治疗在儿童实体肿瘤（包括淋巴瘤及中枢神经系统肿瘤）中的应用进展进行综述。
- Abstract:
- In recent years, targeted therapy has been applied extensively for pediatric solid tumors and some revolutionary advances have brought great hopes to children with unresectable, relapsed and refractory tumors. This review summarized the performance of targeted therapy for pediatric solid tumors.based on clinical trials in the past 5 years.
参考文献/References:
[1] Smith MA, Altekruse SF, Adamson PC, et al.Declining childhood and adolescent cancer mortality[J].Cancer, 2014, 120(16):2497-2506.DOI:10.1002/cncr.28748.
[2] Roberts PJ, Der CJ.Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer[J].Oncogene, 2007, 26(22):3291-3310.DOI:10.1038/sj.onc.1210422.
[3] Gross AM, Wolters PL, Dombi E, et al.Selumetinib in children with inoperable plexiform neurofibromas[J].N Engl J Med, 2020, 382(15):1430-1442.DOI:10.1056/NEJMoa1912735.
[4] Eckstein OS, Allen CE, Williams PM, et al.Phase Ⅱ study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations:arm E of the NCI-COG pediatric MATCH trial[J].J Clin Oncol, 2022, 40(20):2235-2245.DOI:10.1200/JCO.21.02840.
[5] Trippett T, Toledano H, Campbell Hewson Q, et al.Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMATRIX-cobi):a multicenter, phase I/II study[J].Target Oncol, 2022, 17(3):283-293.DOI:10.1007/s11523-022-00888-9.
[6] Jones DTW, Kocialkowski S, Liu L, et al.Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas[J].Cancer Res, 2008, 68(21):8673-8677.DOI:10.1158/0008-5472.CAN-08-2097.
[7] Lassaletta A, Mistry M, Arnoldo A, et al.Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma[J].J Clin Oncol, 2016, 34(15_suppl):10509.DOI:10.1200/JCO.2016.34.15_suppl.10509.
[8] Hargrave DR, Bouffet E, Tabori U, et al.Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma:results from a phase I/IIa study[J].Clin Cancer Res, 2019, 25(24):7303-7311.DOI:10.1158/1078-0432.CCR-19-2177.
[9] Winstead E.Dabrafenib-trametinib combination approved for solid tumors with BRAF mutations[EB/OL].(2022-07-21)[2023-02-27].https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors.
[10] Soucy TA, Smith PG, Milhollen MA, et al.An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer[J].Nature, 2009, 458(7239):732-736.DOI:10.1038/nature07884.
[11] Zhou LS, Jia LJ.Targeting protein neddylation for cancer therapy[J].Adv Exp Med Biol, 2020, 1217:297-315.DOI:10.1007/978-981-15-1025-0_18.
[12] Foster JH, Barbieri E, Zhang LN, et al.The anti-tumor activity of the NEDD8 inhibitor pevonedistat in neuroblastoma[J].Int J Mol Sci, 2021, 22(12):6565.DOI:10.3390/ijms22126565.
[13] Foster J, Muscal JA, Minard CG, et al.Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615)[J].J Clin Oncol, 2019, 37(15_suppl):e21521.DOI:10.1200/JCO.2019.37.15_suppl.e21521.
[14] Morris SW, Kirstein MN, Valentine MB, et al.Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma[J].Science, 1994, 263(5151):1281-1284.DOI:10.1126/science.8122112.
[15] Mossé YP, Voss SD, Lim MS, et al.Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor:a Children’s Oncology Group study[J].J Clin Oncol, 2017, 35(28):3215-3221.DOI:10.1200/JCO.2017.73.4830.
[16] Mossé YP, Laudenslager M, Longo L, et al.Identification of ALK as a major familial neuroblastoma predisposition gene[J].Nature, 2008, 455(7215):930-935.DOI:10.1038/nature07261.
[17] Padovan-Merhar OM, Raman P, Ostrovnaya I, et al.Enrichment of targetable mutations in the relapsed neuroblastoma genome[J].PLoS Genet, 2016, 12(12):e1006501.DOI:10.1371/journal.pgen.1006501.
[18] Foster JH, Voss SD, Hall DC, et al.Activity of crizotinib in patients with ALK-Aberrant relapsed/refractory neuroblastoma:a Children’s Oncology Group study (ADVL0912)[J].Clin Cancer Res, 2021, 27(13):3543-3548.DOI:10.1158/1078-0432.CCR-20-4224.
[19] Bresler SC, Weiser DA, Huwe PJ, et al.ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma[J].Cancer Cell, 2014, 26(5):682-694.DOI:10.1016/j.ccell.2014.09.019.
[20] Bonvini P, Zin A, Alaggio R, et al.High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma[J].Br J Cancer, 2013, 109(12):3084-3091.DOI:10.1038/bjc.2013.653.
[21] Wierdl M, Tsurkan L, Chi LY, et al.Targeting ALK in pediatric RMS does not induce antitumor activity in vivo[J].Cancer Chemother Pharmacol, 2018, 82(2):251-263.DOI:10.1007/s00280-018-3615-7.
[22] Food and Drug Administration. Cabozantinib (CABOMETYX)[EB/OL].[2023-06-27].https://www.fda.gov/drugs/resources-information-approved-drugs/cabozantinib-cabometyx.
[23] Food and Drug Administration.[EB/OL]. FDA approves cabo-zantinib for differentiated thyroid cancer[2023-06-27]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-differentiated-thyroid-cancer.
[24] Chuk MK, Widemann BC, Minard CG, et al.A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors:trial ADVL1211, a report from the Children’s Oncology Group[J].Pediatr Blood Cancer, 2018, 65(8):e27077.DOI:10.1002/pbc.27077.
[25] Akshintala S, Widemann BC, Barkauskas DA, et al.Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors:Children’s Oncology Group study (ADVL1622)[J].J Clin Oncol, 2021, 39(15_suppl):10010.DOI:10.1200/JCO.2021.39.15_suppl.10010.
[26] Matsuki M, Okamoto K, Dezso Z, et al.Abstract 3266:antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines[J].Cancer Res, 2016, 76(14_Supplement):3266.DOI:10.1158/1538-7445.AM2016-3266.
[27] Gaspar N, Venkatramani R, Hecker-Nolting S, et al.Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050):a multicentre, open-label, multicohort, phase 1/2 study[J].Lancet Oncol, 2021, 22(9):1312-1321.DOI:10.1016/S1470-2045(21)00387-9.
[28] Nakagawa M, Oda Y, Eguchi T, et al.Expression profile of class I histone deacetylases in human cancer tissues[J].Oncol Rep, 2007, 18(4):769-774.
[29] Lane AA, Chabner BA.Histone deacetylase inhibitors in cancer therapy[J].J Clin Oncol, 2009, 27(32):5459-5468.DOI:10.1200/JCO.2009.22.1291.
[30] Jaboin J, Wild J, Hamidi H, et al.MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors[J].Cancer Res, 2002, 62(21):6108-6115.
[31] Bukowinski A, Chang B, Reid JM, et al.A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors:Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN)[J].Pediatr Blood Cancer, 2021, 68(4):e28892.DOI:10.1002/pbc.28892.
[32] Meng XB, Gao JZ, Gomendoza SMT, et al.Recent advances of WEE1 inhibitors and statins in cancers with p53 mutations[J].Front Med (Lausanne), 2021, 8:737951.DOI:10.3389/fmed.2021.737951.
[33] Cole KA, Ijaz H, Surrey L, et al.Abstract CT029:pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan:a Children’s Oncology Group study (ADVL1312)[J].Cancer Res, 2021, 81(13_Supplement):CT029.DOI:10.1158/1538-7445.AM2021-CT029.
[34] Cole KA, Pal S, Kudgus RA, et al.Phase Ⅰ clinical trial of the wee1 inhibitor adavosertib (AZD1775) with irinotecan in children with relapsed solid tumors:a COG phase I consortium report (ADVL1312)[J].Clin Cancer Res, 2020, 26(6):1213-1219.DOI:10.1158/1078-0432.CCR-19-3470.
[35] Mueller S, Cooney T, Yang XD, et al.Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma:a Children’s Oncology Group phase I consortium study[J].Neurooncol Adv, 2022, 4(1):vdac073.DOI:10.1093/noajnl/vdac073.
[36] Carol H, Boehm I, Reynolds CP, et al.Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer[J].Cancer Chemother Pharmacol, 2011, 68(5):1291-1304.DOI:10.1007/s00280-011-1618-8.
[37] Otto T, Horn S, Brockmann M, et al.Stabilization of N-Myc is a critical function of Aurora a in human neuroblastoma[J].Cancer Cell, 2009, 15(1):67-78.DOI:10.1016/j.ccr.2008.12.005.
[38] DuBois SG, Mosse YP, Fox E, et al.Phase Ⅱ trial of alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma[J].Clin Cancer Res, 2018, 24(24):6142-6149.DOI:10.1158/1078-0432.CCR-18-1381.
[39] Mossé YP, Fox E, Teachey DT, et al.A phase Ⅱ study of alisertib in children with recurrent/refractory solid tumors or leukemia:Children’s Oncology Group phase Ⅰ and pilot consortium (ADVL0921)[J].Clin Cancer Res, 2019, 25(11):3229-3238.DOI:10.1158/1078-0432.CCR-18-2675.
[40] de Murcia JM, Niedergang C, Trucco C, et al.Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells[J].Proc Natl Acad Sci U S A, 1997, 94(14):7303-7307.DOI:10.1073/pnas.94.14.7303.
[41] Murai J, Huang SYN, Das BB, et al.Trapping of PARP1 and PARP2 by clinical PARP inhibitors[J].Cancer Res, 2012, 72(21):5588-5599.DOI:10.1158/0008-5472.CAN-12-2753.
[42] Brenner JC, Feng FY, Han S, et al.PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma[J].Cancer Res, 2012, 72(7):1608-1613.DOI:10.1158/0008-5472.CAN-11-3648.
[43] Schafer ES, Rau RE, Berg SL, et al.Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma:a Children’s Oncology Group Phase 1 Consortium study (ADVL1411)[J].Pediatr Blood Cancer, 2020, 67(2):e28073.DOI:10.1002/pbc.28073.
[44] Paugh BS, Zhu XY, Qu CX, et al.Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas[J].Cancer Res, 2013, 73(20):6219-6229.DOI:10.1158/0008-5472.CAN-13-1491.
[45] Ehnman M, Missiaglia E, Folestad E, et al.Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments[J].Cancer Res, 2013, 73(7):2139-2149.DOI:10.1158/0008-5472.CAN-12-1646.
[46] Epstein JA, Song B, Lakkis M, et al.Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor[J].Mol Cell Biol, 1998, 18(7):4118-4130.DOI:10.1128/MCB.18.7.4118.
[47] Blandford MC, Barr FG, Lynch JC, et al.Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage:a report from the Children’s Oncology Group[J].Pediatr Blood Cancer, 2006, 46(3):329-338.DOI:10.1002/pbc.20466.
[48] Mascarenhas L, Ogawa C, Laetsch TW, et al.Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors[J].Cancer Med, 2021, 10(3):843-856.DOI:10.1002/cam4.3658.
[49] Xing T, Zhang YL, Li XK, et al.Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma:a case report[J].Transl Lung Cancer Res, 2021, 10(1):483-486.DOI:10.21037/tlcr-19-644.
[50] Tap WD, Wagner AJ, Sch?ffski P, et al.Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas:the ANNOUNCE randomized clinical trial[J].JAMA, 2020, 323(13):1266-1276.DOI:10.1001/jama.2020.1707.
[51] Khandwala HM, Mccutcheon IE, Flyvbjerg A, et al.The effects of insulin-like growth factors on tumorigenesis and neoplastic growth[J].Endocr Rev, 2000, 21(3):215-244.DOI:10.1210/edrv.21.3.0399.
[52] Weigel B, Malempati S, Reid JM, et al.Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors:a report from the Children’s Oncology Group[J].Pediatr Blood Cancer, 2014, 61(3):452-456.DOI:10.1002/pbc.24605.
[53] Malempati S, Weigel B, Ingle AM, et al.Phase Ⅰ/Ⅱ trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma:a report from the Children’s Oncology Group[J].J Clin Oncol, 2011, 30(3):256-262.DOI:10.1200/JCO.2011.37.4355.
[54] Wagner LM, Fouladi M, Ahmed A, et al.Phase Ⅱ study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma:a report from the Children’s Oncology Group[J].Pediatr Blood Cancer, 2015, 62(3):440-444.DOI:10.1002/pbc.25334.
[55] Malempati S, Weigel BJ, Chi YY, et al.The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma:a report from the Children’s Oncology Group[J].Cancer, 2019, 125(2):290-297.DOI:10.1002/cncr.31770.
[56] Wan XL, Yeung C, Heske C, et al.IGF-1R inhibition activates a YES/SFK bypass resistance pathway:rational basis for co-targeting IGF-1R and Yes/SFK kinase in rhabdomyosarcoma[J].Neoplasia, 2015, 17(4):358-366.DOI:10.1016/j.neo.2015.03.001.
[57] Akshintala S, Bernstein D, Glod J, et al.Results of a phase Ⅰ trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS)[J].J Clin Oncol, 2022, 40(16_suppl):11561.DOI:10.1200/JCO.2022.40.16_suppl.11561.
[58] Nazha B, Inal C, Owonikoko TK.Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy[J].Front Oncol, 2020, 10:1000.DOI:10.3389/fonc.2020.01000.
[59] Gupta A, Cripe TP.Immunotherapies for pediatric solid tumors:a targeted update[J].Paediatr Drugs, 2022, 24(1):1-12.DOI:10.1007/s40272-021-00482-y.
[60] Ladenstein R, P?tschger U, Valteau-Couanet D, et al.Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN):a multicentre, randomised, phase 3 trial[J].Lancet Oncol, 2018, 19(12):1617-1629.DOI:10.1016/S1470-2045(18)30578-3.
[61] Furman WL, McCarville B, Shulkin BL, et al.Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy:updated results of a phase II study using hu14.18K322A[J].J Clin Oncol, 2022, 40(4):335-344.DOI:10.1200/JCO.21.01375.
[62] Hingorani P, Krailo M, Buxton A, et al.Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma:a report from the Children’s Oncology Group[J].Eur J Cancer, 2022, 172:264-275.DOI:10.1016/j.ejca.2022.05.035.
[63] Hodi FS, O’Day SJ, McDermott DF, et al.Improved survival with ipilimumab in patients with metastatic melanoma[J].N Engl J Med, 2010, 363(8):711-723.DOI:10.1056/NEJMoa1003466.
[64] Merchant MS, Wright M, Baird K, et al.Phase Ⅰ clinical trial of ipilimumab in pediatric patients with advanced solid tumors[J].Clin Cancer Res, 2016, 22(6):1364-1370.DOI:10.1158/1078-0432.CCR-15-0491.
[65] Davis KL, Fox E, Merchant MS, et al.Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412):a multicentre, open-label, single-arm, phase 1-2 trial[J].Lancet Oncol, 2020, 21(4):541-550.DOI:10.1016/S1470-2045(20)30023-1.
[66] Davis KL, Fox E, Isikwei E, et al.A phase Ⅰ/Ⅱ trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors:a children’s oncology group study ADVL1412[J].Clin Cancer Res, 2022, 28(23):5088-5097.DOI:10.1158/1078-0432.CCR-22-2164.
[67] Geoerger B, Zwaan CM, Marshall LV, et al.Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX):a multicentre phase 1-2 study[J].Lancet Oncol, 2020, 21(1):134-144.DOI:10.1016/S1470-2045(19)30693-X.
[68] Winter C, Pawel B, Seiser E, et al.Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status[J].Pediatr Blood Cancer, 2008, 51(1):10-16.DOI:10.1002/pbc.21475.
[69] Pode-Shakked N, Shukrun R, Mark-Danieli M, et al.The isolation and characterization of renal cancer initiating cells from human Wilms’ tumour xenografts unveils new therapeutic targets[J].EMBO Mol Med, 2013, 5(1):18-37.DOI:10.1002/emmm.201201516.
[70] Geller JI, Pressey JG, Smith MA, et al.ADVL1522:a phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-a Children’s Oncology Group study[J].Cancer, 2020, 126(24):5303-5310.DOI:10.1002/cncr.33195.
[71] Modak S, Zanzonico P, Grkovski M, et al.B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors:results of a phase I study[J].J Clin Oncol, 2020, 38(36):4283-4291.DOI:10.1200/JCO.20.01974.
[72] Kramer K, Pandit-Taskar N, Kushner BH, et al.Phase 1 study of intraventricular 131I-omburtamab targeting B7H3(CD276)-expressing CNS malignancies[J].J Hematol Oncol, 2022, 15(1):165.DOI:10.1186/s13045-022-01383-4.
[73] Ligon JA, Wessel KM, Shah NN, et al.Adoptive cell therapy in pediatric and young adult solid tumors:current status and future directions[J].Front Immunol, 2022, 13:846346.DOI:10.3389/fimmu.2022.846346.
[74] Straathof K, Flutter B, Wallace R, et al.Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma[J].Sci Transl Med, 2020, 12(571):eabd6169.DOI:10.1126/scitranslmed.abd6169.
[75] Heczey A, Xu X, Courtney AN, et al.Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma:updated phase 1 trial interim results[J].Nat Med, 2023, 29(6):1379-1388.DOI:10.1038/s41591-023-02363-y.
[76] Majzner R, Ramakrishna S, Mochizuki A, et al.EPCT-14.GD2 CAR T-cells mediate clinical activity and manageable toxicity in children and young adults with H3K27M-mutated DIPG and spinal cord DMG[J].Neuro Oncol, 2021, 23(Supplement_1):i49-i50.DOI:10.1093/neuonc/noab090.200.
[77] Sterner RC, Sterner RM.CAR-T cell therapy:current limitations and potential strategies[J].Blood Cancer J, 2021, 11(4):69.DOI:10.1038/s41408-021-00459-7.
相似文献/References:
[1]朱媛,高怡瑾,冯一,等.实体瘤患儿治疗期间营养状况及影响因素分析[J].临床小儿外科杂志,2022,21(01):36.[doi:10.3760/cma.j.cn.101785-202101003-007]
Zhu Yuan,Gao Yijin,Feng Yi,et al.Nutritional status and influencing factors of children with solid tumors during treatment[J].Journal of Clinical Pediatric Surgery,2022,21(07):36.[doi:10.3760/cma.j.cn.101785-202101003-007]
[2]莫绪明,笪敏.中国儿童胸部实体肿瘤诊疗现状[J].临床小儿外科杂志,2022,21(03):201.[doi:10.3760/cma.j.cn101785-202202029-001]
Mo Xuming,Da Min.Current status of diagnosing and treating thoracic solid tumors in Chinese children[J].Journal of Clinical Pediatric Surgery,2022,21(07):201.[doi:10.3760/cma.j.cn101785-202202029-001]
[3]陈志华,纪新婷,顾硕.BRAF突变及其靶向治疗在儿童脑胶质瘤中的应用与挑战[J].临床小儿外科杂志,2023,22(07):601.[doi:10.3760/cma.j.cn101785-202201049-001]
Chen Zhihua,Ji Xinting,Gu Shuo.Application of BRAF mutations and targeted therapy in pediatric brain gliomas: successes and challenges[J].Journal of Clinical Pediatric Surgery,2023,22(07):601.[doi:10.3760/cma.j.cn101785-202201049-001]
[4]吴晔明.迎接以TRK抑制剂为代表的儿童泛肿瘤靶向药物时代的到来[J].临床小儿外科杂志,2023,22(07):607.[doi:10.3760/cma.j.cn101785-202303020-002]
Wu Yeming.Arrival of the era of pan-tumor targeted drugs for children represented by TRK inhibitors[J].Journal of Clinical Pediatric Surgery,2023,22(07):607.[doi:10.3760/cma.j.cn101785-202303020-002]
[5]龙俊汕,张京,苏小霞,等.儿童神经母细胞瘤靶向治疗的研究进展[J].临床小儿外科杂志,2023,22(07):619.[doi:10.3760/cma.j.cn101785-202303039-004]
Long Junshan,Zhang Jing,Su Xiaoxia,et al.Research advances of targeted therapy for neuroblastoma in children[J].Journal of Clinical Pediatric Surgery,2023,22(07):619.[doi:10.3760/cma.j.cn101785-202303039-004]
[6]张鑫,金倩涯,袁晓军.青少年和成人神经母细胞瘤诊疗策略和挑战:病例报告并文献复习[J].临床小儿外科杂志,2023,22(07):625.[doi:10.3760/cma.j.cn101785-202306028-005]
Zhang Xin,Jin Qianya,Yuan Xiaojun.Challenges and strategies in the diagnosis and treatment of neuroblastoma in adolescents and adults: one case report with a literature review[J].Journal of Clinical Pediatric Surgery,2023,22(07):625.[doi:10.3760/cma.j.cn101785-202306028-005]
[7]李艳,张从志,尹顺花,等.儿童输注GD2单克隆抗体Naxitamab期间的镇痛方案初探[J].临床小儿外科杂志,2023,22(07):630.[doi:10.3760/cma.j.cn101785-202303043-006]
Li Yan,Zhang Congzhi,Yin Shunhua,et al.Preliminary study of analgesic during infusion of GD2 monoclonal antibody naxitamab in children[J].Journal of Clinical Pediatric Surgery,2023,22(07):630.[doi:10.3760/cma.j.cn101785-202303043-006]
[8]廖文戈,朱俊杰,张昊东,等.三维可视化技术在儿童实体肿瘤手术中的应用价值研究[J].临床小儿外科杂志,2023,22(07):655.[doi:10.3760/cma.j.cn101785-202112034-010]
Liao Wenge,Zhu Junjie,Zhang Haodong,et al.Application of three-dimensional visualization technology for pediatric solid tumors[J].Journal of Clinical Pediatric Surgery,2023,22(07):655.[doi:10.3760/cma.j.cn101785-202112034-010]
备注/Memo
收稿日期:2023-04-29。
基金项目:国家自然科学基金（82172852）
通讯作者:董岿然,Email:kuirand@hotmail.com